Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis

[Background & Aims] Although off-label use of sofosbuvir-containing regimens occurs regularly in patients with hepatitis C virus (HCV) infection undergoing dialysis for severe renal impairment or end-stage renal disease (ESRD), these regimens are not licensed for this indication, and there is an...

Descripción completa

Detalles Bibliográficos
Autores: Borgia, Sergio M., Dearden, Janet, Yoshida, Eric M., Shafran, Stephen D., Brown, Ashley, Ben-Ari, Ziv, Cramp, Matthew E., Cooper, Curtis, Foxton, Matthew, Fernández-Rodríguez, Conrado M., Esteban, Rafael, Hyland, Robert, Lu, Sophia, Kirby, Brian J., Meng, Amy, Markova, Svetlana, Dvory-Sobol, Hadas, Osinusi, Anu O., Bruck, Rafael, Ampuero, Javier, Ryder, Stephen D., Agarwal, Kosh, Fox, Raymond, Shaw, David, Haider, Shariq, Willems, Bernard, Lurie, Yoav, Calleja, José Luis, Gane, Edward J.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2019
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/213341
Acceso en línea:http://hdl.handle.net/10261/213341
Access Level:acceso abierto
Palabra clave:Direct-acting antivirals
ESRD
Severe renal impairment
Chronic hepatitis C infection
HCV, SVR12, drug safety
Descripción
Sumario:[Background & Aims] Although off-label use of sofosbuvir-containing regimens occurs regularly in patients with hepatitis C virus (HCV) infection undergoing dialysis for severe renal impairment or end-stage renal disease (ESRD), these regimens are not licensed for this indication, and there is an absence of dosing recommendations in this population. This study evaluated the safety and efficacy of sofosbuvir/velpatasvir in patients with HCV infection with ESRD undergoing dialysis.

Similares en LA Referencia